Oragenics, Inc.

Oragenics, Inc. converted its remaining Series A and B Preferred Shares into common stock, simplifying its capital structure and eliminating $2.35 million in liquidation preference. This move aligns with the company's commitment to creating long-term shareholder value and advancing its pipeline of neurological and rare disease treatments.

Oragenics, Inc. updates on 2024 milestones for ONP-002, a neurosteroid for concussion treatment, including strengthened clinical leadership, successful cardiotoxicity and genotoxicity tests, and partnership with Avance Clinical. The company plans to initiate Phase II trials, aiming for FDA approval as the first concussion drug.

Oragenics, Inc. (NYSE:OGEN) closed an offering of 3,078,378 shares and pre-funded warrants for 5,028,206 shares at $0.55/share and $0.549/warrant. Post-closing, 8,659,071 shares and 5,028,206 warrants are outstanding, with a $0.001 exercise price per warrant.